

A Hugh Mostafid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4835111/publications.pdf>

Version: 2024-02-01

109
papers

5,587
citations

159585

30
h-index

85541

71
g-index

113
all docs

113
docs citations

113
times ranked

4920
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 62.e13-62.e20.	1.6	21
2	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and T1c). <i>European Urology</i> , 2021, 79, 1011-1020.	1.9	559
3	Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. <i>European Urology</i> , 2022, 82, 182-192.	1.9	25
4	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. <i>European Urology Focus</i> , 2022, , .	3.1	4
5	Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria. <i>World Journal of Urology</i> , 2021, 39, 97-103.	2.2	13
6	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. <i>European Urology</i> , 2021, 79, 62-79.	1.9	532
7	Early recurrence and the need for re-resection following Photodynamic diagnosis-assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group. <i>Journal of Clinical Urology</i> , 2021, 14, 65-72.	0.1	1
8	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. <i>European Urology Oncology</i> , 2021, 4, 12-19.	5.4	26
9	What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?. <i>BJU International</i> , 2021, 128, 225-235.	2.5	9
10	En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. <i>World Journal of Urology</i> , 2021, 39, 3353-3358.	2.2	12
11	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021, 4, 182-191.	5.4	54
12	En Bloc Resection of Bladder Tumor—Is It the Way Forward?. <i>Frontiers in Surgery</i> , 2021, 8, 685506.	1.4	0
13	Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. <i>Bladder Cancer</i> , 2021, 7, 307-315.	0.4	3
14	The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer—a multicentre observational study. <i>BJU International</i> , 2021, 128, 440-450.	2.5	30
15	Management of NMIBC during BCG shortage and COVID-19. <i>Trends in Urology & Men's Health</i> , 2021, 12, 7-11.	0.4	3
16	No "one size fits all"™ approach in the management of high-risk non-muscle invasive bladder cancer. <i>Scandinavian Journal of Urology</i> , 2021, 55, 53-53.	1.0	26
17	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020, 6, 479-489.	3.1	72
18	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 440-448.	1.6	27

#	ARTICLE	IF	CITATIONS
19	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
20	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. <i>European Urology</i> , 2020, 78, 893-906.	1.9	112
21	Indications and Complications of Androgen Deprivation Therapy. <i>Seminars in Oncology Nursing</i> , 2020, 36, 151042.	1.5	3
22	Rapid, Low-Cost Dielectrophoretic Diagnosis of Bladder Cancer in a Clinical Setting. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2020, 8, 1-5.	3.7	9
23	Cystoscopic surveillance for bladder cancer: Learning the lessons forced upon us by the Covid-19 pandemic*. <i>Scandinavian Journal of Urology</i> , 2020, 54, 367-368.	1.0	1
24	Neoadjuvant Intravesical Therapy for Non-muscle-invasive Bladder Cancer: A New Approach for Old Agents?. <i>European Urology</i> , 2020, 78, 863-864.	1.9	2
25	Consensus Definition and Prediction of Complexity in Transurethral Resection or Bladder Endoscopic Dissection of Bladder Tumours. <i>Cancers</i> , 2020, 12, 3063.	3.7	7
26	An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. <i>European Urology</i> , 2020, 78, 546-569.	1.9	77
27	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. <i>European Urology</i> , 2020, 77, 669-670.	1.9	30
28	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin vs surgical management in low-risk non-muscle-invasive bladder cancer. <i>BJU International</i> , 2020, 125, 817-826.	2.5	27
29	IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. <i>International Journal of Surgery Protocols</i> , 2020, 21, 8-12.	1.1	6
30	TULA in recurrent non-muscle invasive bladder cancer. <i>Trends in Urology & Men's Health</i> , 2020, 11, 18-19.	0.4	0
31	Exploring patients' experience and perception of being diagnosed with bladder cancer: a mixed-methods approach. <i>BJU International</i> , 2020, 125, 669-678.	2.5	18
32	Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage. <i>Current Opinion in Urology</i> , 2020, 30, 365-369.	1.8	23
33	Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. <i>BMJ Open</i> , 2020, 10, e041005.	1.9	16
34	Does urinary cytology have a role in haematuria investigations?. <i>BJU International</i> , 2019, 123, 74-81.	2.5	25
35	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Tj ETQq1 1 0.784314 rgBT / Overlock 10	1.9	936
36	Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5818-5831.	7.0	86

#	ARTICLE	IF	CITATIONS
37	Mixed methods approach to exploring patients' perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. <i>BJU International</i> , 2019, 124, 408-417.	2.5	12
38	The beginning of the end for asymptomatic microscopic haematuria. <i>Scandinavian Journal of Urology</i> , 2019, 53, 7-7.	1.0	0
39	Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness. <i>BMJ Open</i> , 2019, 9, e022268.	1.9	16
40	The inflammatory potential of diet and bladder cancer risk: results from a prospective cohort study. <i>Translational Andrology and Urology</i> , 2019, 8, S491-S492.	1.4	0
41	EAU/ESMO consensus statements on the management of advanced and variant bladder cancer: an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	1.2	96
42	Intravesical BCG: where do we stand? Past, present and future. <i>Journal of Clinical Urology</i> , 2019, 12, 425-435.	0.1	1
43	Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. <i>Journal of Internal Medicine</i> , 2019, 285, 436-445.	6.0	20
44	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , 2019, 123, 947-958.	2.5	9
45	BOXIT: A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). <i>European Urology</i> , 2019, 75, 593-601.	1.9	27
46	Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. <i>European Urology</i> , 2019, 75, 63-71.	1.9	96
47	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. <i>European Urology Focus</i> , 2019, 5, 205-223.	3.1	103
48	Grading of Urothelial Carcinoma and The New World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016. <i>European Urology Focus</i> , 2019, 5, 457-466.	3.1	112
49	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2019, 5, 224-241.	3.1	74
50	Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2019, 202, 1111-1119.	0.4	20
51	Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. <i>European Urology</i> , 2018, 74, 10-14.	1.9	78
52	Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials. <i>Trials</i> , 2018, 19, .	1.6	0
53	Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?. <i>Journal of Urology</i> , 2018, 200, 973-980.	0.4	62
54	Prevention of bladder cancer incidence and recurrence. <i>Current Opinion in Urology</i> , 2018, 28, 88-92.	1.8	44

#	ARTICLE	IF	CITATIONS
55	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. <i>European Urology</i> , 2018, 73, 111-122.	1.9	627
56	Guideline of guidelines: asymptomatic microscopic haematuria. <i>BJU International</i> , 2018, 121, 176-183.	2.5	76
57	Genetic polymorphisms may explain association between alcohol consumption and bladder cancer risk in East Asian men. <i>Translational Andrology and Urology</i> , 2018, 7, S252-S254.	1.4	3
58	Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. <i>Bladder Cancer</i> , 2018, 4, 395-401.	0.4	55
59	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , 2018, 4, 525-528.	3.1	8
60	T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues. <i>European Urology</i> , 2018, 74, 609-610.	1.9	1
61	What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. <i>Current Opinion in Urology</i> , 2018, 28, 570-576.	1.8	18
62	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> , 2017, 72, 801-813.	1.9	205
63	A core outcome set for localised prostate cancer effectiveness trials. <i>BJU International</i> , 2017, 120, E64-E79.	2.5	48
64	Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>Eur Urol</i> 2017;71:447-61. <i>European Urology</i> , 2017, 71, e173-e174.	1.9	9
65	Advances in intravesical drug delivery systems to treat bladder cancer. <i>International Journal of Pharmaceutics</i> , 2017, 532, 105-117.	5.2	58
66	Is 4 days hospital stay post robotic radical cystectomy feasible; A multidisciplinary enhanced recovery program after minimal invasive surgery challenge. <i>Clinical Nutrition ESPEN</i> , 2017, 19, 79.	1.2	0
67	PD36-06 IS FOUR DAYS HOSPITAL STAY AFTER ROBOTIC ASSISTED RADICAL CYSTECTOMY FEASIBLE? A MULTIDISCIPLINARY ENHANCED RECOVERY PROGRAM CHALLENGE. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
68	PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
69	Time to re-evaluate and refine transurethral resection in bladder cancer?. <i>BJU International</i> , 2016, 118, 9-10.	2.5	3
70	Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16016-e16016.	1.6	5
71	Diagnosis and treatment of non-muscle-invasive bladder cancer. <i>Trends in Urology & Men's Health</i> , 2015, 6, 23-27.	0.4	3
72	Predicting Outcomes in Bladder Cancer: Are We Any Good and Could We Do Better?. <i>European Urology</i> , 2015, 68, 254-255.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Therapeutic Options in High-risk Non-muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Guérin. <i>European Urology</i> , 2015, 67, 359-360.	1.9	62
74	Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements. <i>Journal of Clinical Urology</i> , 2014, 7, 90-98.	0.1	15
75	So Much Cost, Such Little Progress. <i>European Urology</i> , 2014, 66, 263-264.	1.9	13
76	The Safe and Economical Care of Ta Bladder Cancer. <i>Urology Practice</i> , 2014, 1, 176-183.	0.5	1
77	Does the Nonurologic Scientific Community Understand Urothelial Bladder Cancer?. <i>European Urology</i> , 2014, 66, 601-602.	1.9	4
78	BCG immunotherapy for bladder cancer—the effects of substrain differences. <i>Nature Reviews Urology</i> , 2013, 10, 580-588.	3.8	65
79	Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. <i>British Journal of Cancer</i> , 2012, 106, 496-507.	6.4	28
80	Mesh erosion following laparoscopic incisional hernia repair. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2012, 16, 223-226.	2.0	14
81	Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). <i>BJU International</i> , 2012, 109, 1579-1582.	2.5	35
82	Quality Improvement in Multidisciplinary Cancer Teams: An Investigation of Teamwork and Clinical Decision-Making and Cross-Validation of Assessments. <i>Annals of Surgical Oncology</i> , 2011, 18, 3535-3543.	1.5	97
83	Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations. <i>European Urology</i> , 2010, 57, 607-614.	1.9	117
84	IS IT TIME TO REDESIGN THE HAEMATURIA CLINIC?. <i>BJU International</i> , 2010, 105, 585-588.	2.5	12
85	The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2010, 105, 2-7.	2.5	11
86	Editorial Comment to Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma <i>in situ</i> of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group. <i>International Journal of Urology</i> , 2010, 17, 766-767.	1.0	0
87	Immediate Postoperative Instillation of Intravesical Mitomycin in Theatre: Outcome and Effect on Recurrence of Non Muscle-Invasive Bladder Cancer. <i>Current Urology</i> , 2009, 3, 72-75.	0.6	0
88	Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. <i>BJU International</i> , 2009, 103, 726-729.	2.5	9
89	IMPROVED DETECTION AND REDUCED EARLY RECURRENCE OF NON-MUSCLE-INVASIVE BLADDER CANCER USING HEXAMINOLAEVULINATE FLUORESCENCE CYSTOSCOPY: RESULTS OF A MULTICENTRE PROSPECTIVE RANDOMIZED STUDY (PC B305). <i>BJU International</i> , 2009, 104, 889-890.	2.5	8
90	THE BAUS UROLOGICAL CANCER OBSERVATORY. <i>BJU International</i> , 2009, 104, 562-562.	2.5	1

#	ARTICLE	IF	CITATIONS
91	The Use of the NMP22 BladderChek Test for Bladder Cancer to Optimise Investigations in a One-Stop Haematuria Clinic. <i>British Journal of Medical and Surgical Urology</i> , 2008, 1, 126-130.	0.2	6
92	The management of hydronephrosis in patients undergoing TURBT. <i>International Urology and Nephrology</i> , 2007, 38, 483-486.	1.4	5
93	Case report: differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-Guérin treatment for high-risk superficial bladder cancer. <i>International Urology and Nephrology</i> , 2007, 39, 1039-1041.	1.4	3
94	Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. <i>BJU International</i> , 2006, 97, 509-512.	2.5	25
95	Measles, mumps and rubella - the urologist's perspective. <i>International Journal of Clinical Practice</i> , 2006, 60, 335-339.	1.7	14
96	Planning percutaneous nephrolithotomy using multidetector computed tomography urography, multiplanar reconstruction and three-dimensional reformatting. <i>BJU International</i> , 2005, 95, 1280-1284.	2.5	84
97	RE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS. <i>Journal of Urology</i> , 2005, 173, 1433-1433.	0.4	2
98	Do patients with frank haematuria referred under the two-week rule have a higher incidence of bladder cancer?. <i>Annals of the Royal College of Surgeons of England</i> , 2005, 87, 345-347.	0.6	7
99	Emergency dorsal slit for balanitis with retention. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 205-206.	2.0	3
100	A novel device for reconstituting and delivering intravesical chemotherapy. <i>BJU International</i> , 2003, 92, 492-492.	2.5	2
101	The responsiveness of the ICSmale questionnaire to outcome: evidence from the ICS-â€ˆBPHâ€™™ study. <i>BJU International</i> , 2001, 83, 243-248.	2.5	25
102	The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate. <i>BJU International</i> , 2001, 88, 217-220.	2.5	20
103	The selfâ€™expanding metallic ureteric stent in the longâ€™term management of benign ureteric strictures. <i>BJU International</i> , 2001, 88, 339-342.	2.5	43
104	Radio-Contrast Enhancement of a Urinary Tract Calculus. <i>Urologia Internationalis</i> , 1999, 62, 127-129.	1.3	3
105	Leydig cell tumour of the testis: a rare cause of male infertility. <i>BJU International</i> , 1998, 81, 651-651.	2.5	5
106	The testicular 'tumour' of adrenogenital syndrome: an unusual cause of male infertility. <i>BJU International</i> , 1998, 81, 649-650.	2.5	3
107	RE: POSSIBLE MECHANISMS OF ACTION OF TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE ON BENIGN PROSTATIC HYPERPLASIA SYMPTOMS A NEUROHISTOCHEMICAL STUDY. <i>Journal of Urology</i> , 1998, 159, 209-210.	0.4	0
108	A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia. <i>BJU International</i> , 1997, 80, 116-122.	2.5	18

#	ARTICLE	IF	CITATIONS
109	Interstitial Radiofrequency Therapy of the Prostate: Results of a Pilot Study. Journal of Urology, 1996, 155, 1946-1949.	0.4	3